• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Nivolumab Phase 3 Trial in NSCLC Stopped Early; Superior OS

Article

Mid-trial evaluation by an independent Data Monitoring Committee found overall survival with Opdivo (nivolumab) in the Checkmate-017 trial was significantly better than the control arm. BMS now plans to submit results to the FDA for approval of the PD-1 inhibitor in lung cancer.

Opdivo

Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase 3 study evaluating versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer was stopped early because an assessment conducted by the independent Data Monitoring Committee concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving compared to the control arm. The company will share these data—which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer—with health authorities.

Complete press release by BMS: http://bit.ly/14NW37U

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.